Warning! GuruFocus detected
2 Severe warning signs
with 038.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
NovoCure Ltd
NAICS : 339112
SIC : 5047
ISIN : JE00BYSS4X48
Description
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.41 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.9 | |||||
| Debt-to-EBITDA | -6.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.72 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.8 | |||||
| 3-Year EBITDA Growth Rate | -39.9 | |||||
| 3-Year EPS without NRI Growth Rate | -43 | |||||
| 3-Year Book Growth Rate | -5.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.67 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.18 | |||||
| 9-Day RSI | 38.16 | |||||
| 14-Day RSI | 36.37 | |||||
| 3-1 Month Momentum % | -34.22 | |||||
| 6-1 Month Momentum % | 26.98 | |||||
| 12-1 Month Momentum % | 36.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 1.42 | |||||
| Cash Ratio | 1.27 | |||||
| Days Inventory | 103.86 | |||||
| Days Sales Outstanding | 38.24 | |||||
| Days Payable | 247.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | -3.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.33 | |||||
| Operating Margin % | -28.17 | |||||
| Net Margin % | -27.86 | |||||
| FCF Margin % | -11.45 | |||||
| ROE % | -46.72 | |||||
| ROA % | -14.19 | |||||
| ROIC % | -61.82 | |||||
| 3-Year ROIIC % | -26.87 | |||||
| ROC (Joel Greenblatt) % | -111.28 | |||||
| ROCE % | -15.32 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.68 | |||||
| PB Ratio | 6.21 | |||||
| Price-to-Tangible-Book | 6.22 | |||||
| EV-to-EBIT | -16 | |||||
| EV-to-Forward-EBIT | -7.92 | |||||
| EV-to-EBITDA | -17.64 | |||||
| EV-to-Revenue | 3.2 | |||||
| EV-to-Forward-Revenue | 3.23 | |||||
| EV-to-FCF | -28.75 | |||||
| Price-to-GF-Value | 0.59 | |||||
| Price-to-Projected-FCF | 7.16 | |||||
| Price-to-Net-Current-Asset-Value | 9.92 | |||||
| Price-to-Net-Cash | 28.12 | |||||
| Earnings Yield (Greenblatt) % | -6.25 | |||||
| FCF Yield % | -3.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovoCure Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 560.854 | ||
| EPS (TTM) (€) | -1.454 | ||
| Beta | 0.71 | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 116.21 | ||
| 14-Day RSI | 36.37 | ||
| 14-Day ATR (€) | 0.67253 | ||
| 20-Day SMA (€) | 19.335 | ||
| 12-1 Month Momentum % | 36.05 | ||
| 52-Week Range (€) | 11.095 - 32.57 | ||
| Shares Outstanding (Mil) | 109.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovoCure Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovoCure Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NovoCure Ltd Frequently Asked Questions
What is NovoCure Ltd(FRA:038)'s stock price today?
The current price of FRA:038 is €18.84. The 52 week high of FRA:038 is €32.57 and 52 week low is €11.10.
When is next earnings date of NovoCure Ltd(FRA:038)?
The next earnings date of NovoCure Ltd(FRA:038) is 2025-05-02 Est..
Does NovoCure Ltd(FRA:038) pay dividends? If so, how much?
NovoCure Ltd(FRA:038) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers